Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 18:12:991378.
doi: 10.3389/fonc.2022.991378. eCollection 2022.

Thorax radiotherapy using 18F-positron emission tomography/computed tomography-guided precision radiotherapy is a prognostic factor for survival in patients with extracranial oligometastatic non-small cell lung cancer:A two-center propensity score-matched analysis

Cheng-Sen Liu  1 , Ying-Qiu Song  1 , Run-Ze Wang  1 , Zheng Wang  2 , Rong He  2 , Ke Xu  2 , Chen-Yu Wang  3 , Yu Wu  1 , Ye Wang  1 , Xiao-Fang Zhang  1 , Guang Li  4 , Tian-Lu Wang  1
Affiliations

Thorax radiotherapy using 18F-positron emission tomography/computed tomography-guided precision radiotherapy is a prognostic factor for survival in patients with extracranial oligometastatic non-small cell lung cancer:A two-center propensity score-matched analysis

Cheng-Sen Liu et al. Front Oncol. .

Abstract

Background: This retrospective study compared positron emission tomography (PET)/computed tomography (CT) and CT in the treatment of extracranial oligometastatic non-small-cell lung cancer (NSCLC) and explored the impact of thorax radiotherapy (TRT) on patient survival.

Methods: We reviewed the medical records of Chinese patients with stage IV extracranial oligometastatic NSCLC who underwent PET/CT or CT at two centers. Propensity score matching (PSM) was used to control differences in patient characteristics between the maintenance chemotherapy alone and TRT plus maintenance chemotherapy groups.

Results: We analyzed 192 eligible patients. The median survival time was better in patients who received PET/CT than in those who only received CT (n = 192, 16 months vs. 6 months, p<0.001). Subgroup analysis showed the median survival time was significantly longer in the TRT plus maintenance group than in the chemotherapy alone group in patients who underwent PET/CT examinations (n = 94, 25 months vs. 11 months, p<0.001). However, there was no statistical difference in survival between both groups in patients who underwent CT examinations (n = 98, 8 months vs. 5 months, p = 0.180). A multifactorial analysis revealed a more favorable prognosis in patients who underwent PET/CT evaluation (HR: 0.343, 95% CI: 0.250-0.471, p <0.001) and TRT (HR: 0.624, 95% CI: 0.464-0.840, p = 0.002), than in those who did not. PSM was consistent with these results.

Conclusions: PET/CT-guided TRT is associated with improved clinical outcomes in patients with stage IV extracranial oligometastatic NSCLC.

Keywords: extracranial oligometastatic; non-small cell lung cancer; positron emission tomography/computed tomography; prognosis; thorax radiotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flowchart depicting selection of the study population.
Figure 2
Figure 2
(A, B) Kaplan–Meier curve of overall survival for patients who did and did not receive PET/CT in the overall population (before PSM n=192,after PSM n=122). (C, D) Kaplan–Meier curve of overall survival for patients who did and did not receive TRT in the CT group (before PSM n=98, after PSM n=61). (E, F) Kaplan–Meier curve of overall survival for patients who did and did not receive TRT in the PET/CT group(before PSM n=94,after PSM n=61).
Figure 3
Figure 3
Analysis of OS among patients in the PET/CT group VS. CT group. Subgroup analysis of OS among patients in the PET/CT group TRT VS. No TRT.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol (1995) 13(1):8–10. doi: 10.1200/JCO.1995.13.1.8 - DOI - PubMed
    1. Kalinauskaite GG, Tinhofer II, Kufeld MM, Kluge AA, Grün AA, Budach VV, et al. . Radiosurgery and fractionated stereotactic body radiotherapy for patients with lung oligometastases. BMC Cancer (2020) 20:404. doi: 10.1186/s12885-020-06892-4 - DOI - PMC - PubMed
    1. Weichselbaum RR. The 46th David a. karnofsky memorial award lecture: Oligometastasis-from conception to T reatment. J Clin Oncol (2018) 36(32):3240–50. doi: 10.1200/JCO.18.00847 - DOI - PubMed
    1. Foster CC, Pitroda SP, Weichselbaum RR. Staging the metastatic spectrum through integration of clinical and molecular features. J Clin Oncol (2019) 37:1270–6. doi: 10.1200/JCO.18.02021 - DOI - PubMed
    1. Pitroda SP, Weichselbaum RR. Integrated molecular and clinical staging defines the spectrum of metastatic cancer. Nat Rev Clin Oncol (2019) 16:581–8. doi: 10.1038/s41571-019-0220-6 - DOI - PubMed